Komaromi Selye Janos Korhaz
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The cardiology unit at Komaromi Selye Janos Korhaz conducts research aimed at preventing heart attacks, strokes, and related complications in adults at high cardiovascular risk. Studies explore new lipid‑lowering agents, innovative RNA‑based treatments, and combination regimens for patients with atherosclerotic cardiovascular disease or heart failure with preserved ejection fraction.
- LDL‑C lowering therapies and PCSK9 inhibition
- RNA‑based approaches for mixed dyslipidemia
- Combination treatments for diabetes‑related cardiovascular risk
- Strategies to reduce major adverse cardiovascular events
- Long‑term safety assessments in high‑risk populations
By focusing on safety, efficacy, and long‑term patient‑centered outcomes, the site seeks to advance therapeutic options that lower major adverse cardiovascular events and improve quality of life.
Nutritional and Metabolic Diseases
Research in the metabolic program targets obesity, type 2 diabetes, and overweight conditions that increase cardiovascular burden. Trials evaluate novel peptide agents, dual‑agonist drugs, and lifestyle‑integrated strategies to achieve sustainable weight loss and better glycemic control.
- GLP‑1 and dual agonist therapies for weight reduction
- Impact of metabolic drugs on cardiovascular outcomes
- Renal benefits in patients with metabolic syndrome
- Adjunct lifestyle counseling with pharmacologic treatment
- Comparative effectiveness of new peptide candidates
The overarching aim is to demonstrate that effective weight‑management therapies can also reduce cardiovascular morbidity and improve overall metabolic health.
Respiratory Tract Diseases
The respiratory research line at the hospital investigates new inhaled combination therapies for patients with severe asthma that remains uncontrolled despite standard treatment. Studies assess lung‑function improvement, reduction of exacerbations, and safety of triple‑component inhalers.
- Triple therapy inhaler efficacy in uncontrolled asthma
- Reduction of asthma exacerbations with combination inhalers
- Lung function enhancement using novel bronchodilator blends
- Patient‑reported outcomes and quality‑of‑life measures
- Safety profile of inhaled corticosteroid/long‑acting bronchodilator combos
Ultimately, the goal is to enhance respiratory health and lessen the daily impact of asthma on patients’ lives.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Novo Nordisk A/S1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S5trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Komaromi Selye Janos Korhaz
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 3 | Unknown | 2023-01-30 | 2025-10-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.